# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Julius Caesar (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-AC001-SYN
- Date: 2026-08-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lucius Fairbanks-Okonkwo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week follow-up after recurrent spells of collapse; test results and neurology consultation today. **S**

## History of present illness

Julius Caesar returns two weeks after his first visit. He saw Dr. Lindqvist-Adeyemi of neurology this morning. He has had no further spell, though he woke once from a vivid, frightening dream, confused for a minute or two, which happens every few weeks. The EEG showed intermittent left temporal sharp waves. The MRI showed no new stroke but an old small infarct in the left posterior temporal lobe and moderate small-vessel white matter changes, with no tumor, vascular malformation, or cyst. CT angiography showed a small calcified plaque at the left carotid bifurcation, under 30 percent. The echocardiogram showed mild left ventricular thickening, no clot, and no shunt. The 14-day monitor showed sinus rhythm throughout; the one event he marked, light-headedness on standing up quickly, was in sinus rhythm. He has taken lisinopril every morning without cough or dizziness but did not keep the home blood pressure log. He has not driven, has showered rather than bathed, and has not ridden. He wants to know what the spells are and when he can drive again. **S**

| Element | Detail |
|---|---|
| Spells | None since the first visit; one confused awakening from a vivid dream |
| Tests | EEG left temporal sharp waves; MRI chronic left temporal cortical infarct, no acute infarct; CTA carotid plaque under 30 percent; echo no source of embolism; 14-day monitor sinus rhythm |
| Medicines | Lisinopril 10 mg daily; no cough or dizziness |
| Home blood pressure | Log not kept |
| Safety | Not driving, swimming, or riding |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or weight loss |
| Cardiovascular | Negative | No chest pain or palpitations; brief light-headedness on standing quickly |
| Neurological | Positive | One confused awakening from a vivid dream; no weakness, numbness, speech, or vision change; occasional mild headaches |
| Psychiatric | Negative | Impatient but not low in mood |

4 systems reviewed. **S**

## Current medications

- Lisinopril 10 mg oral tablet, one tablet by mouth daily **S**
- Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth at bedtime **S**
- Aspirin 81 mg delayed-release tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 140/88 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 75.8 kg; BMI 22.9 kg/m². All vital signs are synthetic.

Sodium: 140 mmol/L; Potassium: 4.5 mmol/L; Creatinine: 1.02 mg/dL; eGFR: 86 mL/min/1.73 m². All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 0.98 mg/dL at baseline, 1.02 mg/dL at this visit **S**
- eGFR: 91 mL/min/1.73 m² at baseline, 86 mL/min/1.73 m² at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; alert and composed |
| Cardiovascular | Regular rhythm; no carotid bruit; blood pressure 140/88 mmHg |
| Neurological | Normal speech, naming, and repetition; visual fields full to confrontation; no pronator drift; normal strength, sensation, coordination, and gait |
| Mouth | Tongue laceration healed |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Recurrent transient episodes of collapse: resolved into a diagnosis** (R56.9). The spells are seizures. A rising feeling, staring with lip-smacking, a bitten tongue, and confusion lasting many minutes afterwards point to seizures rather than syncope, and the ECG, the orthostatic blood pressures, the echocardiogram, and two weeks of monitoring show no cardiac cause. A transient ischemic attack causes a sudden loss of function lasting minutes, not loss of awareness with jerking and a long confused recovery, and the arteries show no significant narrowing. The EEG and the MRI agree on a left temporal source. **S**
   - Resolved: the diagnosis is recorded as focal epilepsy (PRB-004) from the chronic infarct (PRB-005).
2. **Focal epilepsy with a structural vascular cause** (G40.209). Under the ILAE 2017 classification: focal impaired-awareness seizures with automatisms, one evolving to a bilateral tonic-clonic seizure, with a structural (vascular) cause. Three unprovoked seizures meet the ILAE definition of epilepsy, and the infarct and the EEG both predict recurrence. Treatment is advised, as Dr. Lindqvist-Adeyemi recommends. **S**
   - Levetiracetam 500 mg twice daily from today.
   - Teaching about irritability, low mood, and drowsiness, which usually settle; call at once with any thoughts of self-harm.
   - Seizure diary; no missed doses.
   - PHQ-9 at the four-week visit.
3. **Chronic left temporal cortical infarct** (I69.398). An ischemic infarct that was never recognized as a stroke but now causes seizures. Treated with secondary stroke prevention. The echocardiogram and the first monitor found no source of embolism. **S**
   - Aspirin 81 mg daily.
   - Atorvastatin 80 mg at bedtime; lipid panel at 4 to 12 weeks.
   - A second ambulatory monitor from today for four more weeks, to look for atrial fibrillation.
   - STOP-Bang score 3 (blood pressure, age, male sex): home sleep apnea test ordered.
   - MoCA at the next visit.
4. **Hypertension** (I10). 140/88 mmHg on lisinopril 10 mg, down from 152/94; still above the target of 130/80. Potassium 4.5 mmol/L and creatinine 1.02 mg/dL, up 4 percent: safe to continue. **S**
   - Continue lisinopril 10 mg.
   - Home blood pressure log twice daily with a memory cuff; a second medicine at the next visit if still above target.
5. **Hyperlipidemia** (E78.5). LDL 158 mg/dL; the target after an ischemic infarct with carotid plaque is below 70 mg/dL. **S**
   - Atorvastatin 80 mg as above; report muscle aches.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (target below 130/80 mmHg) | Every visit | Completed today | 140/88 mmHg on lisinopril 10 mg; above target |
| Self-management | Home blood pressure monitoring | Daily while treatment is adjusted | Deferred | Missed: he did not keep the home log asked for at intake during a busy fortnight. No harm judging by today's office reading (down from 152/94 to 140/88 mmHg) and normal potassium and creatinine. Corrective action: a memory cuff that stores readings, set up in the office today, and a member of his staff to remind him; readings reviewed at the next visit |
| Laboratory | Potassium and creatinine after starting an ACE inhibitor | One to two weeks after starting or changing the dose | Completed today | Potassium 4.5 mmol/L; creatinine 1.02 mg/dL (0.98 at baseline); eGFR 86 |
| Imaging | 12-lead ECG | At baseline | Up to date | Sinus rhythm, left ventricular hypertrophy by voltage, normal intervals (intake) |
| Imaging | Ambulatory rhythm monitoring for atrial fibrillation | At least 30 days within six months of the event | Ordered | 14-day patch: sinus rhythm throughout. A second monitor for four more weeks fitted today |
| Imaging | Brain MRI and EEG | At diagnosis | Completed today | MRI: chronic left posterior temporal cortical infarct, moderate white matter changes, no acute infarct or other lesion. EEG: left temporal sharp waves |
| Imaging | Vascular imaging and echocardiogram | At diagnosis of an ischemic infarct | Completed today | CTA: left carotid plaque under 30 percent, no intracranial stenosis. Echo: no thrombus or shunt, ejection fraction 60 percent |
| Laboratory | Lipid panel after starting a statin | 4 to 12 weeks after starting | Due | Atorvastatin 80 mg started today; panel at the ten-week visit |
| Laboratory | Diabetes screen | At baseline | Up to date | HbA1c 5.6 percent at intake |
| Medication safety | Antithrombotic adherence and bleeding | Every visit | Completed today | Aspirin 81 mg started today; dual antiplatelet therapy is for a recent minor stroke or high-risk TIA, not an old infarct |
| Medication safety | Antiseizure medicine: seizures, adherence, and side effects | Every visit | Completed today | Levetiracetam 500 mg twice daily started today, with written teaching |
| Survey | Depression screen (PHQ-9) | At the first visit after the event, then periodically | Up to date | 3 at intake; repeat at four weeks on levetiracetam |
| Survey | Cognitive screen (MoCA) | In the first year after a stroke | Due | At the next visit |
| Examination | Sleep apnea evaluation | Consider after any stroke | Ordered | STOP-Bang 3; home sleep apnea test ordered |
| Examination | Fall risk | Every visit | Completed today | No fall apart from the seizure; seizure precautions cover the risk |
| Examination | Weight and BMI | Every visit | Completed today | 75.8 kg; BMI 22.9 |
| Self-management | Tobacco, alcohol, physical activity, and diet | Every visit | Completed today | Never smoker; little alcohol; Mediterranean-style diet with less salt agreed; walking daily |
| Self-management | Seizure safety and driving | Every visit | Completed today | Not driving; no swimming or riding alone; showers only; seizure action plan given to his staff |
| Referral | Neurology consultation | At presentation | Completed today | Seen today; diagnosis and treatment agreed |

## Goal progress

- Cause of the spells established and explained to him by the neurology visit. Outcome by 2026-08-18: Focal epilepsy with a structural vascular cause, from a chronic left temporal cortical infarct; syncope and transient ischemic attack judged unlikely. **S**
- No seizures on levetiracetam through the ten-week review. In progress; target 2026-10-27. **S**
- Office blood pressure below 130/80 mmHg. In progress; target 2026-10-27. **S**
- LDL cholesterol below 70 mg/dL on a high-intensity statin. In progress; target 2026-10-27. **S**
- No driving, swimming alone, or riding alone while the seizure-free period is counted, with a written seizure action plan for his staff. In progress; target 2026-10-27. **S**

## Medication changes

- Started: Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily **S**
- Started: Atorvastatin 80 mg oral tablet, one tablet by mouth at bedtime **S**
- Started: Aspirin 81 mg delayed-release tablet, one tablet by mouth daily **S**

## Guideline basis

- Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society (2015), American Academy of Neurology and American Epilepsy Society (Neurology)
- Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology (2017), International League Against Epilepsy (Epilepsia)
- ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology (2017), International League Against Epilepsy (Epilepsia)
- ILAE official report: a practical clinical definition of epilepsy (2014), International League Against Epilepsy (Epilepsia)
- Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy (2018), American Academy of Neurology and American Epilepsy Society (Neurology)
- 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope (2017), American College of Cardiology, American Heart Association, and Heart Rhythm Society (Journal of the American College of Cardiology)
- 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2021), American Heart Association and American Stroke Association (Stroke)
- CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, hypertension, and hyperlipidemia monographs (2026), Aether Forge

## Follow-up

- Four-week chronic-care visit with the monitor results, home blood pressure readings, PHQ-9, and MoCA. **S**
- Next scheduled visit 2026-09-15: four-week review of levetiracetam, blood pressure, the second rhythm monitor, mood, and cognition. **S**
